InvestSMART

CSL Limited (ASX:CSL)

ALERT: Price-sensitive ASX Announcement for CSL
Current share price for CSL : $175.500 55.98 (46.84%)+
Announcement
Release
29 Jul 2026 9:21AM
Price at Release
$119.520
Full Release
download
Summary
CSL Limited announced plans to commence clinical trials for its Horizon 2 plasma manufacturing process, a technology designed to significantly increase immunoglobulin yield from plasma. The trials aim to establish the efficacy and safety of this process and to support regulatory submissions to the FDA and EMA. These trials are scheduled to start mid-2027 at CSL's Broadmeadows facility and will coincide with the expansion of their Kankakee, Illinois site. This initiative is part of CSL's broader strategy to enhance operational efficiency and production capabilities.
Key Points
  • CSL Limited is initiating clinical trials for its next generation Horizon 2 plasma manufacturing process.
  • Horizon 2 is a patented technology aimed at enhancing the yield of immunoglobulin from plasma.
  • The clinical trials are part of CSL's efforts to obtain regulatory approvals from the FDA and EMA.
  • Clinical activities are set to begin in mid-2027 using materials from CSL's Broadmeadows facility.
  • The trials will run parallel to the expansion of CSL’s Kankakee, Illinois manufacturing facility.
  • CSL is focusing on operational efficiencies and advanced manufacturing processes as part of its growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.